Anti-malaria drug efficacy and resistance

Artemisinin-based combination therapies (ACTs) has been adopted as first-line treatments for uncomplicated Plasmodium falciparum malaria as an integral part of the recent success in global malaria control. Between 2010 and 2017, an estimated 2.74 billion treatment courses of ACTs was delivered. However, the efficacy of ACTs is endangered by the emergence of resistance to artemisinin and partner drug which becomes a major threat to malaria elimination. We are delighted to present a cross-journal series to highlight the studies on efficiency of ACTs and implications of antimalarial drug resistance.